LGVN Q1 2023 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$238,000-35.7% YoY

Gross Profit

$35,00014.7% margin

Operating Income

-$5M-1981.5% margin

Net Income

-$5M-1952.5% margin

EPS (Diluted)

$-2.21

QoQ Revenue Growth

+96.7%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$421,000

Balance Sheet

Total Assets

$22M

Total Liabilities

$5M

Stockholders' Equity

$16M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$238,000	$370,000	-35.7%
Gross Profit	$35,000	$165,000	-78.8%
Operating Income	-$5M	-$3M	-39.0%
Net Income	-$5M	-$4M	-32.4%